SIL204 treatment may help immune system attack KRAS-driven tumors, research finds – exclusive

by NOWlej | Aug 5, 2026 | JPost | 0 comments

Illustration of a pancreatic tumor surrounded by immune cells (photo credit: Silexion spokesperson)
This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center.

Subscribe to JPost Premium

Recent Posts

Michael J Sacks on the connection between business growth and community investment
Aug 5, 2026 4:09 pm | Business, JPost Biztech
Israeli cyber startup Oligo Security doubles valuation with $60 Million round
Aug 5, 2026 4:00 pm | Innovation, JPost Tech
Netanyahu’s government is accused of fueling West Bank violence – opinion
Aug 5, 2026 4:00 pm | JPost Opinion, Views
The employee relied on AI and made a mistake: Who will pay the price?
Aug 5, 2026 3:35 pm | Innovation, JPost Tech
US primary shakeups and Netanyahu’s Gaza red line
Aug 5, 2026 3:19 pm | JPost

SIL204 treatment may help immune system attack KRAS-driven tumors, research finds – exclusive

Recent Posts

The Jerusalem Post

YnetNews

Arutz Sheva

JTA